Efficacy and safety of anti-D for immune thrombocytopenic purpura in children.
This study was conducted in 20 children (16 males) (mean age 9.2 +/- 4.34y) with immune thrombocytopenic purpura (ITP) to assess the response to anti-D immunoglobulin. Six patients had newly diagnosed ITP, 6 had persistent ITP and 8 had chronic ITP. The overall response rate was 70% (14/20). The median time to response was 3 days (1-13 days). Response to anti-D was not related to age, sex, severity of bleeding, platelet counts at presentation, ABO blood group, or prior steroid or IVIG response.
Naithani
Rahul
R
Department of Hematology, All India Institute of Medical Sciences, New Delhi, India. dr_rahul6@hotmail.com
Kumar
Rajat
R
Mahapatra
M
M
Tyagi
Seema
S
Mishra
Pravas
P
D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D015331:Cohort Studies; D005260:Female; D005334:Fever; D006801:Humans; D007518:Isoantibodies / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D010599:Pharmacokinetics; D010976:Platelet Count; D011696:Purpura, Thrombocytopenic / Q000188:drug therapy* / Q000453:epidemiology; D018029:Rho(D) Immune Globulin
D007518:Isoantibodies; C061961:RHO(D) antibody; D018029:Rho(D) Immune Globulin